SEC Form 4 · accession 0001102624-16-002060
AEOLUS PHARMACEUTICALS, INC. · AOLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Clerici
Director
Period of report
Oct 1, 2013
Accepted (ET)
Feb 3, 2016 · 3:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261734
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (right to buy)F1 | $0.2612 | Oct 1, 2013 | A | 75,000 | A | — | Oct 1, 2023 | Common Stock | 75,000 | 75,000 | D |
| Non-qualified Stock Option (right to buy)F1 | $0.24 | Oct 1, 2014 | A | 75,000 | A | — | Oct 1, 2024 | Common Stock | 75,000 | 75,000 | D |
| Non-qualified Stock Option (right to buy)F1 | $0.25 | Oct 1, 2015 | A | 75,000 | A | — | Oct 1, 2025 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Option will vest in equal monthly installments over a period of twelve months from the date of grant, provided that the Director remains on the Board of Directors of the Company.